secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001213900-23-065890
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics raises $18.5M, advances lead asset stenoparib, reports early IXEMPRA tumor shrinkage data
--------------------------------------------------------------------------------

- Raised $18.5M in new investment capital since January 2023 to fund clinical programs.
- Initiated Phase 1b/2 combination study of stenoparib + dovitinib in early 2023.
- IXEMPRA Phase 2 in Europe shows early signs of tumor shrinkage and stable disease in metastatic breast cancer.
- Stenoparib is now lead clinical asset; advancing in two of three ongoing trials.
- Entered clinical collaboration with FivepHusion for Deflexifol using 5FU-DRP CDx.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023065890/0001213900-23-065890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023065890/ea183319-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-065890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer